Abstract
The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
MeSH Terms
Algorithms
Breast Neoplasms/classification,genetics
Carcinoma in Situ/classification,genetics
Carcinoma, Ductal, Breast/classification,genetics
Carcinoma, Lobular/classification,genetics
DNA, Neoplasm
Female
Fibroadenoma/classification,genetics
Gene Expression
Gene Expression Profiling
Humans
Oligonucleotide Array Sequence Analysis/methods
Tumor Suppressor Protein p53/genetics
Chemicals
DNA, Neoplasm
Tumor Suppressor Protein p53
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Sørlie T
Department of Genetics, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
Perou C M
Tibshirani R
Aas T
Geisler S
Johnsen H
Hastie T
Eisen M B
van de Rijn M
Jeffrey S S
Thorsen T
Quist H
Matese J C
Brown P O
Botstein D
Lønning P E
Børresen-Dale A L
References (20)
20 references, click to expand
-
Gene-expression profiles in hereditary breast cancer.
N Engl J Med. 2001 Feb 22;344(8):539-48
PMID: 11207349
-
Molecular portraits of human breast tumours.
Nature. 2000 Aug 17;406(6797):747-52
PMID: 10963602
-
Significance analysis of microarrays applied to the ionizing radiation response.
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
PMID: 11309499
-
The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease.
Br J Cancer. 1983 May;47(5):629-40
PMID: 6849801
-
The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
Cancer. 1986 Mar 15;57(6):1171-80
PMID: 3943040
-
Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement.
Eur J Cancer Clin Oncol. 1988 Nov;24(11):1685-90
PMID: 3061825
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Science. 1989 May 12;244(4905):707-12
PMID: 2470152
-
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
Histopathology. 1991 Nov;19(5):403-10
PMID: 1757079
-
Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators.
Cancer. 1993 Mar 15;71(6 Suppl):2141-50
PMID: 8443763
-
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
Nat Med. 1995 Oct;1(10):1029-34
PMID: 7489358
-
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.
Genes Chromosomes Cancer. 1995 Sep;14(1):71-5
PMID: 8527388
-
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
Nat Med. 1996 Jul;2(7):811-4
PMID: 8673929
-
Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
J Pathol. 1996 May;179(1):31-8
PMID: 8691341
-
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Clin Chim Acta. 1997 Jun 27;262(1-2):99-119
PMID: 9204213
-
Cluster analysis and display of genome-wide expression patterns.
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
PMID: 9843981
-
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Br J Cancer. 1999 Jan;79(2):300-7
PMID: 9888472
-
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
Science. 1999 Oct 15;286(5439):531-7
PMID: 10521349
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature. 2000 Feb 3;403(6769):503-11
PMID: 10676951
-
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Cancer Res. 2000 Apr 15;60(8):2155-62
PMID: 10786679
-
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Cancer Res. 2001 Mar 15;61(6):2505-12
PMID: 11289122